Addition of FFRct in the diagnostic pathway of patients with stable chest pain to reduce unnecessary invasive coronary angiography (FUSION) : Rationale and design for the multicentre, randomised, controlled FUSION trial.
S P SharmaA HirschM G M HuninkM J M CramerF A A Mohamed HoeseinC A GelukG KramerJ W C GratamaR L BraamP M van der ZeeW YassiS L WoltersC GürlekG PundziuteR VliegenthartRicardo P J BuddePublished in: Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation (2022)
The FUSION trial will evaluate the use of FFRct in stable chest pain patients from the Dutch perspective. The trial is funded by the Dutch National Health Care Institute as part of the research programme 'Potentially Promising Care' and the results will be used to assess if FFRct reimbursement should be included in the standard health care package.
Keyphrases
- study protocol
- healthcare
- clinical trial
- phase iii
- randomized controlled trial
- phase ii
- end stage renal disease
- newly diagnosed
- ejection fraction
- quality improvement
- open label
- chronic kidney disease
- peritoneal dialysis
- palliative care
- double blind
- affordable care act
- cross sectional
- patient reported outcomes
- health information